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ABSTR ACT: Cancer biomarkers have provided great opportunities for improving the management of cancer patients by enhancing the efficiency of early 
detection, diagnosis, and efficacy of treatment. Every cell type has a unique molecular signature, referred to as biomarkers, which are identifiable charac-
teristics such as levels or activities of a myriad of genes, proteins, or other molecular features. Biomarkers can facilitate the molecular definition of cancer, 
provide information about the course of cancer, and predict response to chemotherapy. They offer the hope of early detection as well as tracking disease pro-
gression and recurrence. Current progress in the characterization of molecular genetics of HIV-associated cancers may form the basis for improved patient 
stratification and future targeted or individualized therapies. Biomarker use for cancer staging and personalization of therapy at the time of diagnosis could 
improve patient care. This review focuses on the relevance of biomarkers in the most common HIV-associated malignancies, namely, Kaposi sarcoma, non-
Hodgkin’s lymphoma, and invasive cervical cancer.
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Introduction
Cancer is a genetically and clinically diverse disease, whose 
pathogenesis, aggressiveness, metastatic potential, and response 
to treatment can be different among individual patients.1 
Great variations exist, even between individuals with the same 
type of cancer, suggesting the role of genetic factors in cancer 
pathogenesis. The risk of developing cancer is greatly increased 
in human immunodeficiency virus (HIV) setting, and it 
is increasingly recognized as a complication of HIV infec-
tion.2,3 Cancers with an increased incidence in HIV patients 
include the AIDS-defining malignancies [Kaposi’s sarcoma, 
non-Hodgkin’s lymphoma (NHL), and invasive cervical can-
cer] and other non-AIDS-defining cancers (Hodgkin’s lym-
phoma, hepatocellular carcinoma, and lung cancer).4 Due to 
the complexity and diversity of cancer, the application of per-
sonalized medicine in the management of cancer patients has 
been suggested and encouraged.
Personalized medicine hinges on biomarkers, which are 
highly sensitive and specific in revealing information that is 
relevant for diagnosis, prognosis, and therapy.5,6  Thus, bio-
marker discovery and development are one of the cores of 
personalized medicine for cancer. Cancer biomarkers may be 
discovered using molecular, cellular, and imaging methodolo-
gies focused on drug and disease mechanisms, thus providing 
critical feedback about the interaction of novel therapies with 
their intended target and about the disease itself.7 Biomarkers 
play a role in cancer screening, early diagnosis, prognosis, can-
cer stratification, prediction of treatment efficacy, and adverse 
Flepisi et al
12 Biomarkers in CanCer 2014:6
reaction. A biomarker can consist of genomic and proteomic 
patterns, single genes or proteins, chromosomal abnormalities, 
epigenetic signatures, aberrant microRNA (miRNA), as well 
as imaging changes observed on magnetic resonance imaging 
(MRI) or positron emission tomography (PET) scan. However, 
most biomarkers have both prognostic and predictive value.
Biomarker Definition
Biomarkers are characteristics that are objectively measured 
and evaluated as indicators of normal biological processes, 
pathogenic processes, and pharmacological responses to a 
therapeutic intervention.8,9 In cancer, biomarkers are defined 
as biochemical substances elaborated by cancer cells either due 
to the cause or effect of malignant process.10 However, cancer 
biomarkers must be detectable only in the presence of can-
cer. Cancer biomarkers may be detected in sample matrices 
such as serum, plasma, whole blood, urine, and tissue.11 They 
can be normal endogenous products that are produced at a 
greater rate in cancer cells or the products of newly switched 
on genes that remained inactive in normal cells. Biomarkers 
may include intracellular molecules or proteins in tissues or 
may be released into the circulation and appear in serum, and 
their presence in significant amount may indicate the presence 
of cancer. However, the usefulness of a biomarker lies in its 
ability to provide early indication of a disease or its progres-
sion, and it should be easy to detect and should be measurable 
across populations.12
Cancer Biomarker Classification and Utility
It has been well established that a variety of biomarkers are 
used in risk assessment, early detection, diagnosis, treatment, 
and management of cancer.13,14  Molecular analyses at the 
protein, DNA, RNA, or miRNA levels can contribute to the 
identification of novel tumor subclasses, each with a unique 
prognostic outcome or response to treatment.15  Biomarkers 
enable the characterization of patient populations and quanti-
tation of the extent to which drugs reach intended targets, alter 
proposed pathophysiological mechanisms, and achieve clinical 
outcomes.16 The most valuable biomarkers are highly sensitive, 
specific, reproducible, and predictable, and the majority of US 
Food and Drug Administration (FDA) approved that cancer 
biomarkers are serum-derived single proteins.17,18
Biomarkers can be classified based on different param-
eters such as characteristics and function. Biomarkers that 
are classified according to their functions include type 0 bio-
markers, which measure the natural history of a disease and 
they should correlate over time with known clinical indica-
tors; type I biomarkers are associated with the effectiveness 
of pharmacologic agents; and type II biomarkers, also known 
as surrogate endpoint biomarkers, are intended to substitute 
for clinical endpoints.19  Current cancer biomarkers may be 
grouped into a variety of categories including proteins, gly-
coproteins, oncofetal antigens, hormones, receptors, genetic 
markers, and RNA molecules.11
Cancer biomarkers are also classified into prediction, 
detection, diagnostic, prognostic, and pharmacodynamics 
biomarkers.20 Prognostic biomarkers are based on the distin-
guishing features between benign and malignant tumors. Pre-
dictive biomarkers (also known as response markers) are used 
exclusively in assessing the effect of administering a specific 
drug, thus, allowing clinicians to select a set of chemothera-
peutic agents, which will work best for an individual patient. 
Pharmacodynamic biomarkers are cancer markers utilized in 
selecting doses of chemotherapeutic agents in a given set of 
tumor-patient conditions. Diagnostic markers may be present 
in any stage during cancer development.
HIV-associated Kaposi Sarcoma and its Problems  
in Diagnosis
Kaposi sarcoma (KS) is an endothelial neoplasia that is found 
typically in cutaneous lesions, whose development stages 
entail macules, plaques, and nodules.21 KS is the most com-
mon malignancy in HIV patients. HIV-associated Kaposi sar-
coma (HIV-KS) is a low-grade vascular tumor associated with 
human herpesvirus 8  (HHV8)/KS-associated herpes virus 
infection and is the most aggressive and frequent type of KS.22,23 
KS primarily involves the skin but can also involve the viscera.24 
Multiple mucocutaneous lesions typically evolve from flat 
macule (early or patch stage) into plaques (plaque stage) and 
then nodules (tumor or nodular stage) containing spindle-
shaped tumor cells. KS has a variable clinical course, ranging 
from minimal disease presenting as an incidental finding to 
a rapidly progressing neoplasm that can result in significant 
morbidity and mortality, depending on the specific site of 
involvement.
It poses problems in histologic diagnosis due to its broad 
morphologic spectrum and mimicry of many benign vaso-
proliferative lesions and tumors with a prominent spindle 
component.25 Distinguishing KS from other benign or malig-
nant vascular tumors, as well as other nonvascular spindle cell 
soft tissue neoplasms, can be challenging.26  Early-stage KS 
represents a reactive lesion that can either regress or prog-
ress. Progression is related to the long-lasting expression of 
HHV8 latency genes in KS lesions, including latent nuclear 
antigen-1  (LANA-1),21  cyclin-D1,27,28  and bcl-2.29  HHV8-
related induction of the receptor tyrosine kinase c-kit was 
shown by gene expression profiling in cultured endothelial 
cells to play a key role in KS tumorigenesis.30,31
Biomarkers Used in HIV-KS Diagnosis/Prognosis
The differential diagnosis of KS may include cutaneous angio-
sarcoma, spindle cell hemangioma, dermatofibrosarcoma 
protuberans, vascular transformation of lymph nodes, pilar 
leiomyoma, stasis dermatitis, pyogenic granuloma, and spin-
dled melanoma among others (Table 1).26 Histologically, all 
epidemiologic forms of KS are characterized by the progres-
sive proliferation of spindle-shaped cells and are associated 
with KSHV/HHV8.32 Thus, immunohistochemical  detection 
Cancer biomarkers 
13Biomarkers in CanCer 2014:6
of HHV8  in fixed tissues would be diagnostically useful, 
enabling one to differentiate KS from other entities. In latency, 
HHV8 genes produce numerous proteins that induce or main-
tain KS lesions, including K12, K13/viral FADD-like inter-
feron converting enzyme inhibitory protein (vFLIP), vCyclin, 
and the LANA-1 that modulates cellular transcription.33–35
HHV8  LANA-1  is a protein encoded by open read-
ing frame-73  (ORF73) of the virus’ genome. The protein is 
expressed predominantly during viral latency and appears to 
play a role in viral integration into the host genome. It has 
also been shown to interfere in apoptosis via interactions 
with p53.36  LANA-1  protein may cause dysfunction of cell 
cycle regulatory checkpoints by degrading p53 and inactivat-
ing pRb.37 It has been previously shown that positive immu-
nostaining for HHV8 LANA-1 exhibits high sensitivity and 
specificity, and it is a reliable and cost-effective method for the 
diagnosis of KS and is also useful for distinguishing it from 
the mimickers.21,25,29
Recently, it has been reported that immunohistochemi-
cal staining with D2-40, CD31  (a platelet/endothelial cell 
adhesion molecule, PECAM1), CD34  (a hematopoietic 
progenitor cell surface protein), and FLI1  (Friend leukemia 
virus integration 1) is useful for distinguishing cutaneous KS 
from other diseases.24,38  D2-40  is a novel monoclonal anti-
body, directed against Mr 40000 O-linked sialoglycoprotein, 
which reacts with a fixation resistant epitope on the lymphatic 
endothelium.39  It is considered to be a selective marker of 
lymphatic endothelium.40  Monoclonal antibodies directed 
against CD31  and CD34  are sensitive and specific markers 
of endothelial differentiation that are expressed by the major-
ity of vascular tumors. It has been previously demonstrated 
that immunostaining for CD31 and CD34 can be used as an 
aid in KS diagnosis in routinely processed tissues.41 In a study 
by Rosado and colleagues, it was reported that CD31, CD34, 
D2-40, and FLI1  markers demonstrated high sensitivity in 
both AIDS-related and non-AIDS-related KS as well as in 
stages of tumor progression.38
A number of inflammatory cytokines, peptide growth 
factors, HIV encoded Tat protein, and KSHV/HHV8 gene 
products contribute to KS cell growth and development.42 
HHV8  antigens target cell signaling pathways and deregu-
late apoptosis and immune response through vCyclin, 
vFLIP, bcl-2 oncogene, viral interferon regulating factor, and 
vIL-6.33,43–47  The alterations of immune cells (lymphocytes, 
monocytes, histiocytes, and dendritic cells) have been sug-
gested to play a role in the neoplastic process.48 Immune acti-
vation can cooperate with some growth factors and HIV-1 Tat 
protein in the development and progression of KS.49 HIV-KS 
cells have been shown to produce angiogenic growth fac-
tors and cytokines such as fibroblast growth factors (FGFs), 
tumor necrosis factor-α (TNF-α), interleukin 1 (IL-1), IL-6, 
Tat, and oncostatin M, and express high affinity receptors 
for  several cytokines.50,51 Elevated levels of IL-1, IL-6, and 
TNF-α have been reported in patients with HIV-KS.52
Oncostatin M, a cytokine produced by microphages and 
activated T-lymphocytes, has been shown to be a mitogen for 
HIV-KS derived spindle cells.53 Oncostatin M appears to be 
a major cytokine responsible for maintaining the long-term 
growth of HIV-KS in cell cultures.54  In addition, inflam-
matory cytokines induce the production of a potent auto-
crine growth factor for spindle cells known as basic fibroblast 
growth factor (bFGF). The autologous production of bFGF is 
an important stage in KS tumorigenesis since antisense bFGF 
or anti bFGF antibodies interfere in KS cell growth in tis-
sue culture.42 It has been shown that oncostatin M, IL-1, and 
TNF-α induce KS cell growth by inducing the expression of 
various bFGF isoforms.
HIV-associated NHL and its Problems  
in Diagnosis
NHL refers to a heterogeneous group of hematopoietic malig-
nancies originating in the lymphocytes.55–57 The majority of 
NHL cases (85–90%) arises from B-cell progenitors and 
develops into the various entities largely grouped into low, 
intermediate, and high-grade NHL based on the treated 
natural history and survival patterns.58 NHL comprises many 
subtypes, each with distinct epidemiology, etiology, and fea-
tures (ie, morphology, immunophenotype, and clinical mani-
festations).59,60 Epstein–Barr virus (EBV) has been implicated 
Table 1. summary of current biomarkers in HiV-ks.
BIOMARKER CHANGES SEEN IN HIV-KS REFERENCES
HHV8/Lana-1 elevated 21,22,25,26,29,32
Cyclin D1 elevated 22,27,28 
bcl2 elevated 29,33,35,51
c-kit elevated 30,31
k12 elevated 33,34
k13/vFLiP elevated 33,46,47
vCyclin elevated 35,43,45
P53 suppressed 36,37
prb suppressed 27,33
D2–40 elevated 24,38,40
CD31 elevated 22,24,38,41
CD34 elevated 24,38,41 
FLi1 elevated 38
viL-6 elevated 33,44,52 
Tat elevated 49
bFGF elevated 42
TnF-α elevated 42,52
iL-1 elevated 42,51,52
oncostatin m elevated 42,53,54
Abbreviations: HHV8, human herpesvirus 8; Lana-1, latent nuclear 
antigen-1; bcl2, B-cell lymphoma 2; k13/vFLiP, k13/viral FaDD-like interferon 
converting enzyme inhibitory protein; vCyclin, viral cyclin; prb, retinoblastoma 
protein; FLi1, friend leukemia integration-1 transcription factor; viL-6, viral 
interleukin-6; TnF-α, tumour necrosis factor-α.
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Table 2. summary of current biomarkers in HiV-nHL.
BIOMARKER CHANGES SEEN IN HIV-NHL REFERENCES
LDH elevated 101,105,106
ki-67/miB-1 elevated 61,79,80
CD19, CD20, CD22 elevated 63,89,90
CD79a elevated 63,90
PaX-5 elevated 63,81,81
CD10 elevated 61,62
bcl6 elevated 61,62,65,87
mUm-1 elevated 61,62,65
cmYC Translocation and elevated 73,86,87 
iL-6 elevated 97,99
iL-10 elevated 95,97,99
TnF-α elevated 97,98 
CrP elevated 99,101
sCD23, sCD27, sCD30, sCD44 elevated 48,92,99 
B2m elevated 105,106
CXCL13 elevated 48,92
eBV Dna elevated 108
FLC elevated 97,100
FoXP1 elevated 83,85
Abbreviations: LDH, lactate dehydrogenase; miB-1, e3 ubiquitin-protein ligase miB1; PaX-5, paired box protein 5; bcl6, B-cell lymphoma 6; mUm-1, multiple 
myeloma oncogene 1; iL-6, interleukin 6; iL-10, interleukin 10; TnF-α, tumor necrosis factor-α; CrP, C-reactive protein; sCD23, soluble CD23; sCD44, soluble 
CD44; B2m, beta-2 microglobulin; CXCL13, C-X-C motif chemokine 13; eBV Dna, epstein–Barr virus deoxyribonucleic acid; FLC, free immunoglobulin light chains; 
FoXP1, forkhead box protein P1.
in the development of many NHL subtypes in HIV-infected 
individuals.61 NHL is the second most common malignancy 
in HIV-infected patients, with diffuse large B-cell lymphoma 
(DLBCL) as the most common subtype of HIV-associated 
NHL (HIV-NHL) followed by Burkitt’s lymphoma (BL).62
DLBCLs are heterogeneous diseases that differ in nature 
of the genetic abnormalities, morphologic appearance, clini-
cal features, and patients respond differently to treatment and 
vary in prognosis.63,64  Most DLBCLs are thought to arise 
from normal antigen exposed B-cells that have migrated to 
or through germinal centers.65 Gene expression profiling has 
identified two broad subgroups: those of germinal center ori-
gin, known as germinal centre B-cell like (GCB) lymphomas 
(typically CD10+ and BCL6+); and those arising from cells 
resembling activated B-cells (non-GCB) (typically IRF4/
MUM-1+/- and CD13+).56,66 It has been shown that patients 
with GCB DLBCL have a better progression free and over-
all survival than those with non-GCB DLBCL, irrespective 
of the international prognostic index (IPI) score.67–71 There-
fore, the subclassifications of DLBCL into GCB and non-
GCB may serve as important predictive prognostic factors. 
BL is an aggressive form of NHL derived from germinal cen-
ter B-cells.72 HIV-associated BL is characterized by cMYC 
translocations and overexpression;73 however, EBV infection 
is not necessarily a precursor to transformation.74 NHL is a 
very complex malignancy consisting of several types that are 
also divided into subclasses that differ in treatment response 
and prognosis. This may pose problems in the initial diagno-
sis of NHL. Biomarkers are necessary in the initial evalua-
tion of the patients with newly diagnosed NHL, which must 
establish the precise histologic subtype, the extent, and site 
of disease (localized or advanced, nodal or extranodal). This 
is important in the determination of treatment approach and 
predicting the response to chemotherapy.
Biomarkers Used in HIV-NHL Diagnosis/Prognosis
The first step in the diagnosis of NHL is to obtain good qual-
ity and adequate sample of tissue by excisional biopsy of an 
affected lymph node or other mass lesion for assessment of cel-
lular morphology and nodal architecture (Table 2).75–77 After 
the initial tissue biopsy provides a diagnosis of NHL, the fol-
lowing laboratory tests are performed: complete blood count, 
white blood cell differential, platelet count, and examination 
of the peripheral smear for the presence of atypical cells, 
suggesting peripheral blood and bone marrow involvement; 
biochemical tests including blood urea nitrogen (BUN), cre-
atinine, alkaline phosphatase, aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), lactate dehydroge-
nase (LDH), and albumin; serum calcium, electrolytes, and 
uric acid; serum protein electrophoresis; HIV, hepatitis B, and 
C serology; and beta-2 microglobulin levels (in patients with 
indolent lymphomas).78
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This is followed by pathological evaluations, which 
include flow cytometry or immunohistochemical staining for 
immunophenotype.75 For aggressive lymphomas, this includes 
evaluation of proliferative fraction using Ki-67  or MIB-1 
staining as a more aggressive regimen may be indicated for 
high growth fraction tumors.77 The expression of Ki-67 has 
been associated with poor outcome and survival in DLBCL 
patients.79,80 Immunophenotypic expression patterns of 
DLBCL include positivity for various pan B-cell markers such 
as CD19, CD20, CD22, CD79a, PAX-5, and demonstration of 
immunoglobulin surface light chain restriction by flow cytom-
etry in the majority of cases.63 The presence of positive PAX-5 
immunostaining has been strongly associated with B-cell differ-
entiation as PAX-5 is a B-cell restricted transcription factor.81,82 
Staining for CD10, bcl-6, and MUM-1 are usually routinely 
performed in order to distinguish GCB from non-GCB 
DLBCL.
Fork box protein P1  (FOXP1), an essential transcrip-
tion regulator of B-cell development, has been shown to be 
overexpressed in non-GCB DLBCL as compared with GCB 
DLBCL.71,83,84 FOXP1 has also been associated with poor sur-
vival and prognosis.85 It is now recognized that FOXP1 may 
serve as an additional biomarker for distinguishing non-GCB 
from GCB DLBCL and should be included in the diagnosis/
prognosis of DLBCL. In addition, fluorescence in situ hybrid-
ization (FISH) analysis for cMYC is performed as translo-
cations involving the cMYC occurs in 10–15% of DLBCL 
lymphomas and is associated with a worse outcome.86 MYC 
translocations confers a worse prognosis in patients treated 
with cyclophosphamide, hydroxydaunorubicin, oncovin, and 
prednisone (CHOP), and CHOP plus rituximab (R-CHOP) 
regimens.87 BL expresses a germinal center B-cell phenotype,88 
and the immunophenotypic expression include B-cell anti-
gens CD19, CD20, CD22, CD79a, and PAX-5  along with 
CD10, bcl-6, CD77, Ki-67 or MIB-1 and monotypic surface 
light chains such as IgM.89 BL also expresses CD43, TCL1, 
and CD38 but is negative for CD5, CD23, CD44, CD138, 
CD34, and TdT.90,91
Altered immune mechanisms play a critical role in the 
pathogenesis of NHL, as evidenced by increased rates of 
NHL among HIV-positive patients, transplant recipients, 
and autoimmune disease patients.92,93  A marked increase in 
B-cell activation is commonly seen in HIV infection, which is 
driven by the overproduction of B-cell stimulatory cytokines, 
such as IL-6 and IL-10, as well as by stimulation of B-cells by 
HIV and other microbial antigens.94 In addition, HIV itself 
induces the production of inflammatory cytokines that cause 
B-cell stimulation, proliferation, and activation, and the cell 
lines derived from HIV-NHL have been found to express 
cytokines including interleukin 6, 10, and tumor necrosis 
factor-α.95–98 B-cell activation is characterized by lymphocyte 
proliferation, class switch recombination (CSR), and somatic 
hypermutation, all of which are prone to resultant errors in 
DNA that may lead to lymphomagenesis. B-cell  activation 
leads to the expression of activation induced cytidine deami-
nase (AICDA), a DNA modifying enzyme that mediates 
immunoglobulin gene CSR and somatic hypermutation.99
Various factors associated with B-cell activation, includ-
ing B-cell stimulatory cytokines, as well as soluble serum 
molecules that are associated with B-cell activation, includ-
ing serum immunoglobulins (Ig) and Ig components such 
as free light chains, have been seen to be elevated preceding 
the appearance of HIV-NHL.99,100  In a nested case–control 
study by Breen and colleagues, it was shown that serum lev-
els of molecules associated with B-cell activation including 
IL-6, IL-10, C-reactive protein (CRP), sCD23, sCD27, and 
sCD30  are elevated for several years preceding the diagno-
sis of systemic HIV-NHL.99,101  In addition, De Roos and 
colleagues, in a case–control study within Women’s Health 
Initiative study cohort of 491 cases and 491 controls, showed 
that women with high serum levels of soluble sCD23, sCD27, 
sCD30, sCD44, and CXCL13 biomarkers were at 2.8- to 5.5-
fold increased risk of B-NHL.92 Furthermore, this was con-
firmed by Hussain and colleagues, in a nested case–control 
study of 3768 women, where it was shown that elevated levels 
of sCD27, sCD30, CD23, and CXCL13 were associated with 
subsequent diagnosis of HIV-NHL.48
Factors associated with poor clinical outcome and 
shorter survival in patients with HIV-NHL include CD4 cell 
count 100 mm3, advanced stage disease (III or IV), age over 
35 years, history of injection drug use, elevated serum LDH 
(above normal), Eastern Co-operative Oncology Group per-
formance status (ECOG PS) of more than 2, and the involve-
ment of more than 2  extranodal sites.102–106  Matthews and 
colleagues, in a cohort of 7840 HIV-positive patients, showed 
that age, nadir CD4 cell count, and no prior cART are signifi-
cantly associated with the development of systemic NHL.107 In 
addition, Tedeschi and colleagues showed that low CD4 and 
CD8 cell count and detectable EBV viremia are three indepen-
dent prognostic biomarkers that might help in the management 
of HIV-NHL patients.108 Furthermore, higher HIV viral load 
accompanied by lower CD4 count have been associated with 
the development of HIV-NHL.109,110 It has been shown that 
the risk of HIV-NHL rises substantially in patients with HIV 
RNA levels greater than 100 000  copies/µL and those with 
CD4 lymphocyte counts of less than 50 mm3/µL.111
HIV-associated Cervical Cancer and its Problems  
in Diagnosis
Human papillomavirus (HPV) infection is the most important 
cause of cervical cancer; however, only 2% of cervical HPV will 
develop into cervical cancer.112 Cervical cancer is caused by a per-
sistent infection with high-risk human papillomavirus (hrHPV) 
types, which lead to premalignant precursor lesions known as 
cervical intraepithelial neoplasia (CIN).113 The most common 
histologic types of cervical cancer are squamous cell (69%) 
and adenocarcinoma (25%).114 CIN is characterized by abnor-
mal cellular proliferation, maturation, and nuclear atypia.115 
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CIN may regress to normal or progress to invasive cervical 
cancer if left untreated. Approximately, one-third to one half 
of the cases of CIN I and CIN II regress without treatment. 
However, the more severe the abnormality of the lesion, the 
less likely it is to regress. The accurate grading of CIN lesions 
is important for clinical management of patients, because CIN 
I and CIN II/III lesions are treated differently and inaccurate 
grading results in over or under treatment. This emphasizes the 
need for specific biomarkers to aid objective CIN grading and 
to achieve more accurate diagnosis.
Biomarkers Used in HIV-associated Cervical  
Cancer Diagnosis/Prognosis
The detection of HPV DNA in cervical cancer has been 
proven to be a good diagnostic and risk predictor tool for 
cervical cancer (Table 3).116 The oncogenic process in cervi-
cal cancer is initiated and mediated by the upregulation of 
HPV E6/E7 oncoproteins, and thus, overexpression of these 
oncoproteins is a marker for an increased risk of cervical 
cancer.117–119  The hrHPV subtypes such as 16  and 18  are 
thought to play a role in malignant transformation of cells 
by producing E6 and E7 viral regulatory proteins.33 E6 and 
E7 are involved in cell proliferation and survival. HPV and 
oncogene E6  and E7  expressions are the most important 
markers implicated for cervical cancer.20 Some studies suggest 
that HPV oncogenes E6 and E7 mRNA levels in the uterine 
cervix may be more specific early indicators of predisposition 
to carcinogenesis than DNA levels.120
Ki-67  is a well-known cell proliferation marker, use-
ful for confirmation of the diagnosis in ambiguous cases of 
cervical cancer and CIN grading.121 Ki-67 detects a nuclear 
antigen that is present only in proliferating cells but absent 
in resting cells.122 Ki-67 has been found to be more intensely 
stained in HPV-positive than HPV-negative epithelium. 
P16INK4A (p16) is a cyclin-dependent kinase (cdk) inhibitor 
that functions as a specific biomarker used for identification 
of squamous and glandular dysplastic cervical epithelium with 
tendency to invasive cervical cancer. It has been suggested 
that p16  is overexpressed in cervical epithelial cells that are 
transformed in response to the expression of the hrHPV E7 
oncoprotein.113 In a nested study by Carozzi and colleagues, 
it was shown that p16 overexpression is a marker for CIN2 or 
worse or for its development within 3 years in HPV-positive 
women.123 Ki-67 and p16 are complimentary alternative bio-
markers for HPV-related neoplasia.124,125  Cytokeratin (CK) 
17 is a useful marker for endocervical reserve stem cells, which 
gives rise to metaplasia and antibody to CK17 is used to dif-
ferentiate between immature squamous metaplasia and high-
grade CIN (CIN III).126  CK17  is specific for reserve cells 
and immature metaplastic cells; it is not expressed in cervical 
glandular epithelial cells, squamous cells, or mature squamous 
metaplastic cells.127,128
Overexpression of mini chromosome maintenance 
(MCM) proteins is seen in severe dysplastic lesions,129,130 
and overexpressed cell division cycle protein 6  (CDC6) is 
observed in malignant cervical cancer.131,132  The ribosomal 
protein S12 gene has also been reported as an early molecular 
diagnostic identifier for the screening of cervical cancer and 
is a potential target in cancer gene therapy trials.122,133 Tumor 
suppressor protein p53  is a nuclear phosphoprotein encoded 
by the p53  gene, whose normal function is to control cell 
proliferation and apoptosis. Mutations of the p53  gene are 
frequently found in most invasive cancer, resulting in loss 
of tumor suppressor functions of wild type p53 and gain of 
oncogenic functions. Overexpression of p53  has been sug-
gested to be a possible prognostic marker for cervical cancer.134 
Table 3. summary of current biomarkers in HiV-associated cervical cancer.
BIOMARKER CHANGES SEEN IN HIV ASSOCIATED  
CERVICAL CANCER 
REFERENCES
HPV Dna elevated 20,113,118
HPVe6/e7 elevated 116–120
ki-67 elevated 121,124,125
P16 elevated 113,121,123,124,126
Ck17 elevated 113,126–128
mCm elevated 129,130,132
CDC6 elevated 131,132
ribosomal protein s12 elevated 133
P53 elevated 115,125,134
PCna elevated 115,135,137
miB-1 elevated 137
P63 suppressed 113,136
CD44 elevated 138,139
Abbreviations: HPV Dna, Human papillomavirus deoxyribonucleic acid; P16, cyclin-dependent kinase inhibitor p16; Ck17, cytokeratin 17; mCm, mini chromosome 
maintenance protein; CDC6, cell division cycle protein 6; PCna, proliferating cell nuclear antigen.
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Madhumati and colleagues showed that proliferating cell 
nuclear antigen (PCNA) and P53  expression increases with 
increasing severity of CIN lesions.115  It has been previously 
shown that upregulation of PCNA is closely associated with 
hrHPV and progressive CIN, but does not predict outcome 
in cervical cancer.135 P63, which is a member of the p53 gene 
family, is expressed in the basal and parabasal cells of mature 
cervical, vaginal, and vulval squamous epithelium, and also 
in cervical reserve cells at the transformation zone.113,136  It 
has been shown that MIB-1  may be a useful marker for 
identification of low-grade CIN lesion with high prolifera-
tive index.137 CD44 is a cell adhesion molecule that has been 
reported to be correlated with poor prognosis in invasive cer-
vical cancer.122,138,139  The increased serum CD4+ and CD8+ 
T-cell levels and the presence of large number of natural killer 
(NK) cells have been associated with a favorable response 
in patients with cervical cancer treated with neo-adjuvant 
chemotherapy.
Discussion/Conclusion
Cancer biomarkers offer a great potential for improving the 
management of cancer at every point from screening and detec-
tion, diagnosis, staging, prognosis, and assessment of treat-
ment response.20 Biomarkers offer the hope of early detection 
as well as tracking cancer progression and recurrence.66 Early 
detection may help improve survival of HIV-positive cancer 
patients, as it could help identify HIV-positive individuals at 
most risk of cancer development distinguish aggressive from 
indolent malignancies and track disease progression.
Discovery of new biomarkers suitable for clinical applica-
tion may aid the diagnosis and classification of cancer, which in 
turn, should lead to better patient stratification.140 Biomarkers 
do not need to be cancer specific to be useful; certain proteins 
may help predict response to therapy or aid in the monitor-
ing of disease progression.141 As cancer is increasingly defined 
by dysregulated pathways, relevant biomarkers may cut across 
tumor types without showing tissue specificity. Abundance of 
potential cancer biomarkers have been discovered, however, 
only few of them have been integrated into clinical practice. 
This is due to the fact that some of these biomarkers are not 
highly sensitive and specific for cancer detection. It is well rec-
ognized that the road from biomarker discovery, validation, 
and regulatory approval to the translation into clinical setting 
could be long and difficult.11
A new era is underway in which cancer detection, diag-
nosis, and treatment will be guided increasingly by the molec-
ular attributes of the individual patient.142 The future of cancer 
therapy lies in the use of biomarkers that offer the potential 
to identify and treat cancer years before it is either visible or 
symptomatic. In addition, the future of cancer management 
is expected to be profoundly dependent upon the use of bio-
markers that will guide physicians at every step of disease 
management.143 Cancer biomarkers can be used for the accu-
rate evaluation and management of the disease.
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